Detailansicht

Wissensnetz

Person

Jan-Niklas Eckardt (1991-)

Name	Jan-Niklas Eckardt
Zeit	1991- (Lebensdaten)
Ort	Deutschland
Geschlecht	männlich
Akademischer Grad bzw. Titel	Dr. med.
Weitere Angaben	Dissertation, Georg-August-Universität Göttingen 2020
Datensatztyp	Person
GND-Nummer	1222283484
Datensatz-ID	1222283484
Beteiligt an alle anzeigen Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles Alterations of cohesin complex genes in acute myeloid leukemia : differential co-mutations, clinical presentation and impact on outcome Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study Loss-of-function mutations of BCOR are an independent marker of adverse outcomes in intensively treated patients with acute myeloid leukemia Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia Evaluation der Interaktionen zwischen extrazellulärer Matrix und ausgewählten tumorassoziierten Proteinen mittels Nahinfrarot-Antikörpern

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Jan-Niklas Eckardt (1991-)

Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence

Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles

Alterations of cohesin complex genes in acute myeloid leukemia : differential co-mutations, clinical presentation and impact on outcome

Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome

Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

Loss-of-function mutations of BCOR are an independent marker of adverse outcomes in intensively treated patients with acute myeloid leukemia

Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia

Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia

Evaluation der Interaktionen zwischen extrazellulärer Matrix und ausgewählten tumorassoziierten Proteinen mittels Nahinfrarot-Antikörpern